Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast

International Journal of Cancer

Volumn 120, Issue 2, 2007, Pages 357-361

  Imoto, Shigeru ^a   Wada, Noriaki ^a   Hasebe, Takahiro ^a   Ochiai, Atsushi ^a   Kitoh, Takashi ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Research and Development Center   (Japan)

Author keywords

Breast carcinoma; Prognosis; Serum ErbB 2; Tumor marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 33845637765     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22166     Document Type: Article

References (28)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987:235:177-82.
2. Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, Sakamoto G, Akiyama T, Ogawa M, Shiraishi M, Toyoshima K, Yamamoto T. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 1990;81:489-94.
3. Narita T, Funahashi H, Satoh Y, Takagi H. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992;24:97-102.
4. Isola JJ, Holli K, Oksa H, Teramoto Y, Kallioniemi O-P. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994;73:652-8.
5. Kandl H, Seymour L, Bezwoda WR. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994;70:739-42.
6. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis EO, Blarney RW, Robertson JFR. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996;40:251-5.
7. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Later ML, Gimenzez N, Hage M, Estape J, Ballesta AM. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 1996;16:2295-300.
8. Buzdar AU, Ibrahim NK, Framcis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arum BK, Giordano SH, Crisofanilli M, Frye DK, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor-2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
10. Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, Brodowicz T, Tomek S, Niedermanyr M, Hejna M, Steger GG, Krainer M, Wiltschke C, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004;10:1618-24.
11. Imoto S, Kitoh T, Hasebe T. Serum c-erbB-2 levels in monitoring operable breast cancer patients. Jpn J Clin Oncol 1999;29:336-9.
12. Imoto S, Ohkura H, Sugano K, Sasaki Y, Ito K, Igarashi T, Ohtsu T, Fujii H, Minami H, Hasebe T, Mukai K. Determination of cytosol c-erbB-2 protein in breast cancer by sandwich enzyme immunoassay. Jpn J Clin Oncol 1998;28:92-6.
13. Masuko T, Sugahara K, Kozono M, Otsuki S, Akiyama T, Yamamoto T, Toyoshima K, Hashimoto Y. A murine monoclonal antibody that recognizes as extracellular domain of the human c-erbB-2 protooncogene product. Jpn J Cancer Res 1989;80:10-14.
14. Sugano K, Kawai T, Ishii M, Koyama H, Kitajima M, Kasumi F, Demura R, Nakayama T, Okabe H, Mori S. Clinical evaluation of serum ErbB-2 protein using enzyme immuno assay. Can To Kagakuryoho 1994;21:1255-62 (in Japanese).
15. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
16. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M, Yamamoto H. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 1989;65:1794-1800.
17. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90:1601-8.
18. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta A. c-erbB-2 oncoprotein. CEA, and CA15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998;51:109-19.
19. Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000;89:329-36.
20. Molina R, Filella X, Jo J, Zanon G, Alicarte J, Munoz M, Farrus B, Ballesta AM. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein. CEA and CA15.3) in patients with locoregional breast. Anticancer Res 2003;23:1043-50.
21. Fontana X, Ferrari P, Namer M, Peysson R, Salanon C, Bussiere F. C-erbB-2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res 1994;14:2099-104.
22. Anderson TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL. Detection of c-erbB-2 related protein in sera from breast cancer patients. Acta Oncol 1995;34:499-504.
23. ASCO Tumor Marker Expert Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
24. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35.
25. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DT, Hösch S, Hayes DF. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-25.
26. Lipton A, Ali SM, Leitzel K, Dermer L, Chinchilli V, Eagle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carmey W, Allard J. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-72.
27. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-8.
28. Mehta RR, McDermott JH, Hieken TJ, Marler KC, Patel MK, Wild LD, Gupta TKD. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998;16:2409-16.